⌘K

08:43:46·75d

SECFilingvia Quantisnow

Amendment: SEC Form SCHEDULE 13G/A filed by Enanta Pharmaceuticals Inc.

ByQuantisnow·Wall Street's wire, on your screen.

ENTA· Enanta Pharmaceuticals Inc.

Health Care

Original source

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Companies

ENTA
Enanta Pharmaceuticals Inc.
Health Care

Recent analyst ratings

Mar 26UpdateRodman & Renshaw$20.00
Nov 14UpdateAnalyst-
Oct 1UpdateJefferies$20.00
Jul 28UpdateH.C. Wainwright$20.00
Aug 9UpdateJP Morgan$14.00
Aug 8UpdateJefferies$18.00

Related

PR16d
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
PR22d
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
PR30d
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)
SEC34d
Amendment: SEC Form SCHEDULE 13G/A filed by Enanta Pharmaceuticals Inc.
ANALYST34d
Rodman & Renshaw initiated coverage on Enanta Pharmaceuticals with a new price target
SEC34d
Enanta Pharmaceuticals Inc. filed SEC Form 8-K: Other Events
INSIDER47d
SEC Form 4 filed by Director Vance Terry
INSIDER47d
SEC Form 4 filed by Director Russell Lesley